open-label randomised trial of tolvaptan plus low dose furosemide compared with high dose furosemide in patients with hospitalised heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190805001

Enrollment

Registered

2019-08-05

Start date

2019-08-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

tolvaptan 7.5mg plus furosemide 40&#45

60 mg /day if poor response adjust to tolvaptan 15 mg plus furosemide 40&#45

60 mg/day ,increase dose furosemide 80&#45

100mg/day if poor response increase dose to 160&#45

200mg/day

Active Comparator Drug,No Intervention Drug

tolvaptan with lowdose furosemide ,furosemide dose titration

Eligibility

Sex/Gender

All

Age

18 Years to 0 Years

Inclusion criteria

Inclusion criteria: age> 18 years hospitalised heart faillure by framingham criteria

Exclusion criteria

Exclusion criteria: -patient who receive more than two iv dose of furosemide 1 month or oral > 80 mg/day before randomisation - allergy tolvaptan - patient with serum sodium > 142 mol/L - serum K G3B (GFR= 2

Design outcomes

Primary

Measure	Time frame
daily bodyweight change and urine volume 1year mean and standard deviation ,student t test	—

Secondary

Measure	Time frame
incidence of AKI progression of AKI ,change in serum creatinine 1 year mean and standard deviation ,student t test	—

Countries

thailand

Contacts

Public Contactphattraphorn pratyarattananonmedicine

bhumibhol hospital

pata-dreamy@hotmail.com0875041064

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

open&#45;label randomised trial of tolvaptan plus low dose furosemide compared with high dose furosemide in patients with hospitalised heart failure